Skip Navigation



Annals of Oncology Advance Access published online on July 21, 2009
Annals of Oncology, doi:10.1093/annonc/mdp319
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
21/2/419    most recent
mdp319v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Leyssens, B.
Right arrow Articles by Mombaerts, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leyssens, B.
Right arrow Articles by Mombaerts, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis

B. Leyssens1,*,{dagger}, H. Wildiers2,{dagger}, J. P. Lobelle2, A. Gillis1, R. Paridaens2 and I. Mombaerts1

1 Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium
2 Department of Medical Oncology, University Hospitals Leuven, Leuven, Belgium

* Correspondence to: Dr B. Leyssens, Department of Ophthalmology, University Hospitals Leuven, Kapucijnenvoer 33, B-3000 Leuven, Belgium. Tel: +32-16-33-23-85; Fax: +32-16-33-23-67; E-mail: barbara.leyssens{at}gmail.com

Background: Dacryostenosis is a common side-effect of weekly docetaxel (Taxotere). We investigate the efficacy of eyedrops containing corticosteroids (CS) versus artificial tears (AT) in patients receiving weekly docetaxel in the prevention of dacryostenosis.

Patients and methods: Twenty patients receiving weekly docetaxel were evaluated. Forty eyes were double-blind randomized: AT in one eye and CS in the other eye were administered, six times daily, throughout the docetaxel administration. Patients were assessed for tearing and stenosis at weeks 3, 6, 9 and 26. The primary end point was the incidence of dacryostenosis in each group at 9 weeks.

Results: At 9 weeks, punctal or canalicular stenosis was observed in 9 of 20 (45%) of the CS eyes and 9 of 20 (45%) of the AT eyes. Dacryostenosis was mild in 37 of 40 eyes (93%) and severe in 3 of 40 eyes (8%), with equal distribution in the CS and AT group. Tearing was present in 9 of 20 (45%) of the CS eyes and 8 of 20 (40%) of the AT eyes, of which two eyes without stenosis in each group.

Conclusions: The incidence of dacryostenosis in patients receiving weekly docetaxel was not different for the AT- and the CS-treated eyes. The dacryostenosis was predominantly mild, not leading to surgical interventions.

canalicular stenosis, dacryostenosis, docetaxel, primary prevention, tearing

{dagger} Both authors contributed equally to this work.

Received for publication March 29, 2009. Revision received May 9, 2009. Accepted for publication May 11, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.